A long-term 4+ year, double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events
Patients with type 2 diabetes have increased risk of developing cardiovascular complications. Improved control of hyperglycemia or blood pressure reduces the risk of diabetic complications Administration of bexagliflozin, a potent SGLT2 inhibitor, has been shown to be well tolerated and to decrease HbA1c in subjects with type 2 diabetes. Study THR-1442-C-476 is designed to demonstrate that bexagliflozin also improves glucose control in patients at higher risk of cardiovascular events. There may be additional benefits of bexagliflozin of weight loss and reduction of blood pressure.
Condition | Diabetes Mellitus, Type 2, Diabetes Mellitus Types I and II |
---|---|
Clinical Study Identifier | TX145097 |
Sponsor | Theracos |
Last Modified on | 8 November 2020 |
,
You have contacted , on
Your message has been sent to the study team at ,
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreEvery year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.